What Vitrase Treats: Main Uses and Benefits

Vitrase (Ovine Hyaluronidase) is applied across domains where additional symptomatic support is needed, and is considered relevant in contexts that require enhanced uptake of injected substances. This medication is used in situations involving certain distressing symptoms across three core therapeutic areas. The medication is indicated as an adjuvant in these contexts.

The medication is commonly used across conditions presenting with acute episodes where supportive assistance is needed. These uses include being applied in addressing symptomatic relief by supporting subcutaneous fluid administration for managing mild to moderate dehydration, assisting in the management of drug extravasation injury (leakage) to mitigate localized tissue damage, and is relevant for supporting local anesthetic blocks and certain diagnostic procedures.

Its use contributes to improved comfort for patient groups like geriatric or palliative care individuals by supporting less invasive hydration methods. The medication supports the management of acute complications in situations that involve sudden symptom escalation, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Localized Strain Vitrase may assist in reducing the risk of subsequent localized tissue damage associated with injection complications, supports the body's functional stability during episodes of heightened physiological strain.

Who Can and Cannot Use Vitrase?

This section outlines the officially documented population eligibility and non-eligibility information for Vitrase (Ovine Hyaluronidase) as defined by regulatory authorities.

---

Contraindicated and Restricted Use

Absolute Contraindications: Vitrase is contraindicated in any patient with a known hypersensitivity to hyaluronidase or any component of the formulation.

Specific Restrictions: The medicine must not be injected into or around an infected or acutely inflamed area due to the risk of spreading localized infection. Use is also restricted when the purpose is to enhance the absorption of dopamine or alpha agonist drugs.

---

Age and Physiological Eligibility

Population Group	Regulatory Status
Infants and Children	Use is established, but specific fluid volume limitations apply to clysis solutions in infants and children under three years old.
Older Adults	No specific limitations have been demonstrated based on age.
Pregnancy	Classified as Category C. Use is restricted to situations only if clearly needed, as determined by official labeling.
Lactation	Caution should be exercised when administered to a nursing woman, as it is unknown if the medicine is excreted into human milk.

---

Eligibility is defined by regulatory documents primarily through absolute exclusion based on allergy and conditional exclusions based on the local administration site and co-administered substances. The labeling contains no explicit restrictions based on the patient's hepatic or renal function.

Interactions with other medicines and products

Vitrase (Ovine Hyaluronidase) possesses a focused interaction profile based on its function as an enzyme that alters the permeability of connective tissue.

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Local Anesthetic Agents, Corticosteroids, Antihistamines, Estrogens, Salicylates, Alpha Agonist Drugs
Specific interacting medicines (if explicitly listed)	Dopamine, Furosemide, Benzodiazepines, Phenytoin
Mechanistic basis of interactions	Enzymatic action leading to enhanced dispersion and systemic absorption of co-administered drugs

---

Official Interaction Statements

• Co-administration with Local Anesthetic Agents hastens the onset of effect but shortens the duration of analgesia.
• The enzyme's action results in the increased systemic absorption of co-administered drugs like local anesthetics, which may increase the incidence of systemic reactions.
• The regulatory labels state that Vitrase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.
• Furosemide, the benzodiazepines, and phenytoin are officially documented as being incompatible with hyaluronidase when mixed directly in the same solution.
• Large systemic doses of Salicylates, Corticosteroids (e.g., ACTH, Cortisone), Estrogens, or Antihistamines may render tissues partly resistant to the enzyme, potentially requiring a greater quantity of hyaluronidase for the desired dispersing effect.

---

Connection to the Overall Interaction Profile

The official regulatory documents define the product's interaction structure based on its core enzymatic function to facilitate dispersion and systemic exposure of co-administered medicinal products. This effect is explicitly stated to alter the time-to-onset and overall concentration of various drugs. The profile also includes constraints, such as specific warnings against use with dopamine and alpha agonists, and clear restrictions regarding physical incompatibilities with certain drugs in solution.

Vitrase's mechanism is fundamentally a targeted enzymatic action that physically alters the structure of connective tissue. This effect is temporary, localized, and facilitates rapid dispersion of co-administered substances.

Molecular Action on Extracellular Matrix Viscosity

The drug acts via the enzyme Hyaluronidase, which targets and hydrolyzes the polysaccharide Hyaluronic acid in the tissue's extracellular matrix (ECM). This molecular breakdown results in the depolymerization of the high-viscosity ground substance, which constitutes the first step in the mechanism.

Modulation of Local Tissue Permeability

The immediate physiological consequence of reducing matrix viscosity is a transient increase in local tissue permeability. By lowering the physical resistance within the connective tissue, the enzyme functions as a "spreading factor," which results in a wider and faster distribution of co-administered fluids or medications into the surrounding area.

⏳ Constraint by Enzyme Kinetics

The mechanism is naturally self-limiting; its effect is only temporary because the Hyaluronidase enzyme is cleared from the site and the body naturally regenerates the hyaluronic acid structure. This constraint contributes to the mechanism being localized and fully reversible, typically resolving within one to two days.

Administration and Dosing of Vitrase

Vitrase (Ovine Hyaluronidase) is an injectable medicine whose official use is strictly defined by its role as a procedural adjuvant. The enzyme must be administered via subcutaneous (SC) injection or infiltration, as administration through the intravenous (IV) route is prohibited due to rapid inactivation.

---

Official Unit Dosing and Frequency

Vitrase is supplied as a lyophilized powder for injection that must be reconstituted prior to use. It is intended for single-use, acute administration tied to the medical procedure, not as a scheduled therapy.

Procedure Context	Official Unit Dose (USP Units)
Subcutaneous Fluid Administration	200 Units injected prior to the clysis, facilitating absorption of 1,000 mL or more of solution.
Drug Dispersion Enhancement	50 to 300 Units, most typically 150 Units, added to the injection solution.
Subcutaneous Urography	75 Units injected subcutaneously over each scapula.

---

Preparation and Specific Use Requirements

Once the powder is reconstituted, the resulting solution, if admixed with another drug, should be stored at 15–25°C and used within 6 hours. Appropriate clinical references should be consulted for physical or chemical incompatibilities before mixing Vitrase with other drugs. The final solution is also used for intradermal (ID) skin testing prior to full administration.

Pediatric Administration Rules

For administration in children, specific volume constraints are imposed on the co-administered fluid. For infants and children less than three years old, the volume of a single subcutaneous fluid clysis should be limited to 200 mL. During the neonatal period, the daily dosage of fluid should not exceed 25 mL/kg of body weight, and the administration rate must not be greater than 2 mL per minute.

Research evidence / Overview of Studies for Vitrase (Ovine Hyaluronidase)

---

Evidence for Use in Subcutaneous Fluid Administration (Hydration)

Research has explored the use of Vitrase as an adjunct in subcutaneous fluid administration (hypodermoclysis) for patients requiring hydration when intravenous fluid delivery may be challenging. Studies have focused on measuring the rate and extent of fluid absorption into the systemic circulation. The research monitored outcomes related to systemic or functional imbalance, such as changes in overall hydration status. Findings describe patterns observed in the studies regarding the volume of fluid that was observed to be delivered and absorbed over specific time intervals. The use in this context is recognized in regulatory labeling and supported by long-standing clinical studies and regulatory documentation.

What remains uncertain is the availability of extensive, modern comparative evidence; comparative evidence is lacking against the full range of current standard hydration methods. Additionally, long-term effects are not fully established, as follow-up durations were limited to the acute administration period.

---

Evidence for Use with Other Injected Medicines

Vitrase was studied for its role as a protein that increases diffusion (sometimes called a "spreading factor"), where research examined its combined use with other injectable medicines, such as local anesthetics. These trials explored how the addition of Vitrase may influence the drug's properties at the injection site. Outcomes monitored included the time to onset and duration of action of the co-administered drug, and its pharmacokinetics was monitored in the observed populations.

Clinical studies documented variations in the time required for co-administered drugs to achieve their expected effect when used alongside hyaluronidase. A key point of uncertainty remains because the outcomes observed may be highly dependent on the co-administered drug; evidence quality varies across studies based on the specific formulation being tested. Sample sizes were modest in many trials, and results apply only to the populations studied.

---

Study Duration and Follow-up Assessments

The clinical research for Vitrase primarily focuses on its acute and localized function. Therefore, research explored short-term symptom changes and immediate physiological responses. Follow-up durations were limited in most core studies, often covering the infusion period or the immediate duration of drug action (minutes to a few hours). As a key limitation, the current evidence landscape contains limited information for long-term outcomes. The long-term effects are not fully established, and there is a lack of research observing responses over defined time intervals extending beyond the acute treatment episode.

Key Studies & References A Systematic Review of Hyaluronidase-Assisted Subcutaneous Fluid Administration in Pediatrics and Geriatrics and its Potential Application in the Emergency Department

Common questions about Vitrase (FAQ)

---

Q: How long does the actual hyaluronidase enzyme from Vitrase stay active in the body?

Regulatory information indicates that the enzyme is rapidly inactivated if it enters the bloodstream, which is why intravenous administration is prohibited. For its localized use, the product information reports that the local biological effect may persist for approximately 24 to 48 hours.

---

Q: How quickly does Vitrase start to have its effect after being injected?

The action of the enzyme is characterized as immediate upon injection. When Vitrase is combined with other medications, such as a local anesthetic, it is intended to work quickly to help hasten the onset of the co-administered drug's effects.

---

Q: Are there any signs of a serious allergic reaction to Vitrase that I should watch out for?

Serious systemic hypersensitivity events, such as anaphylactic-like reactions, have been reported in the official product labeling. Other documented symptoms of a serious reaction or toxicity may include local swelling or hives, chills, nausea, dizziness, tachycardia (a fast heartbeat), and hypotension (low blood pressure).

---

Q: How do doctors monitor for signs of toxicity or overdose with hyaluronidase?

Official information regarding toxicity states that if symptoms occur—such as systemic swelling, chills, nausea, vomiting, dizziness, fast heartbeat, or low blood pressure—the enzyme should be immediately discontinued. The regulatory label states that supportive measures should be initiated to manage these symptoms.

---

Q: Is it normal to feel a temporary stinging or burning sensation right after the Vitrase injection?

Yes, official regulatory documents classify pain at the injection site as one of the most frequently reported adverse experiences. This general classification of pain can include temporary sensations such as stinging or burning immediately following the injection.

---

Q: Can Vitrase lose its effectiveness if it's mixed with the wrong type of solution before injection?

Yes, official regulatory documents warn about specific incompatibilities. Certain medications, including furosemide, phenytoin, and the benzodiazepines, have been documented as being incompatible when mixed directly with hyaluronidase solutions.

---

Q: Why is Vitrase mentioned in the context of X-rays or diagnostic imaging?

Vitrase has an official indication for use as an adjunct in a procedure called subcutaneous urography. This is a specific type of X-ray procedure where the enzyme is used to improve the dispersion and absorption of the radiopaque agent (dye) that is injected.

---

Q: Is the breakdown of Vitrase rapid once it enters the bloodstream?

Yes, the official label for Vitrase states that the enzyme is rapidly inactivated if it enters the bloodstream. For this reason, administration is specifically prohibited from being injected directly into a vein.

---

Q: What kind of non-allergic side effects are considered rare but possible with Vitrase?

Official product labeling primarily reports local and allergic reactions. Rare systemic effects, often reported in the context of acute toxicity or overdose, include symptoms like chills, nausea, vomiting, dizziness, tachycardia (fast heart rate), and hypotension (low blood pressure).

---

Q: Does Vitrase affect the way my body processes or clears other drugs?

The primary effect of Vitrase is to increase the spread and systemic absorption of co-administered drugs. For instance, when used with a local anesthetic, the increased absorption is known to shorten the duration of action of that anesthetic. The product information does not specify if it alters how the body breaks down (metabolizes) or excretes (clears) drugs via organs like the liver or kidneys.

---

Q: Is there a chance Vitrase could break down the body's natural hyaluronic acid?

Vitrase works by hydrolyzing (breaking down) hyaluronic acid that is found in the connective tissue's extracellular matrix. This action is transient and localized to the site of administration, resulting in a temporary and reversible increase in tissue permeability.

---

Q: Are there any known long-term side effects or consequences of using Vitrase?

Official regulatory documents state that long-term animal studies have not been performed to assess the enzyme's potential for causing cancer or genetic mutation.

---

Q: What are the most common injection site reactions associated with Vitrase?

According to the official product information, the most frequently reported adverse events have been localized reactions at the site of injection. These may include feelings of pain, visible swelling, and redness.

---

Q: If a person is allergic to other animal-derived proteins, is Vitrase still an option?

Vitrase is contraindicated (should not be used) in any patient with a known allergy to the drug or its components. The regulatory label indicates that a preliminary intradermal skin test can be performed to check for hypersensitivity.

---

Q: Does Vitrase have a specific use in ophthalmology or eye procedures?

The official product labeling does not list an indication (a specific approved use) for Vitrase in ophthalmology or general eye procedures. However, the label contains a safety warning that the product should not be applied directly to the cornea (the front surface of the eye).

---

Q: Are there certain medical conditions where Vitrase is not recommended?

Vitrase is contraindicated (should not be used) if a patient has a known allergy to the drug or its components. Additionally, official regulatory guidelines state that it should not be injected into or around an infected or acutely inflamed area due to the risk of spreading the infection.

Storage and Disposal of Vitrase (Hyaluronidase Injection)

Official regulatory documents define specific storage and handling requirements for Vitrase to maintain the stability of the enzyme.

Storage Conditions

The unopened vial must be stored under refrigeration at a temperature range of 2 C to 8 C (36 F to 46 F). It is mandatory to protect the vial from light, and it must not be frozen.

Stability and Handling

Once the product is prepared as an admixture, it is only stable for a short duration. The admixture must be used within 6 hours of preparation when stored between 15 C and 25 C. Parenteral products should be visually inspected for discoloration prior to use.

Disposal

Vitrase is supplied in a single-dose vial. Any unused portion of the product must be discarded according to appropriate procedures.